Announced details
Commercialized in Japan (cumulative usage and other figures: Not disclosed)
The Company's invention was submitted to and evaluated in an award program organized by the Japan Institute of Invention and Innovation and received an award. Capital, personnel and business relationships: Not disclosed.
Organizer of the National Commendation for Invention. Location, representative, capital and year established: Not disclosed.
FY2026 National Commendation for Invention, Minister of Education, Culture, Sports, Science and Technology Award (First Award Category)
Japan Institute of Invention and Innovation
Patent No. 6797148 and others
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Japan Institute of Invention and Innovation (National Commendation for Invention)
| Item | Details |
|---|---|
| Names of Products / Services Covered | J-Brain Cargo® technology, IZCARGO® (pabinafusp alfa) |
| Counterparty | Japan Institute of Invention and Innovation |
| Counterparty overview | Organizer of the National Commendation for Invention. Location, representative, capital and year established: Not disclosed. |
| Relationship with the Company | The Company's invention was submitted to and evaluated in an award program organized by the Japan Institute of Invention and Innovation and received an award. Capital, personnel and business relationships: Not disclosed. |
| Launch date | 2021 (a drug incorporating J-Brain Cargo® technology obtained marketing approval in Japan) |
| Applicable area | Central nervous system treatments, Lysosomal diseases, Alzheimer's disease, Parkinson's disease, Neuroinflammatory diseases, Neuro-oncology, Nucleic acids, lipid nanoparticles and gene therapy |
| Award/certification name | FY2026 National Commendation for Invention, Minister of Education, Culture, Sports, Science and Technology Award (First Award Category) |
| Awarding / certifying body | Japan Institute of Invention and Innovation |
| Registration number and expiry date | Patent No. 6797148 and others |
| Usage history | Commercialized in Japan (cumulative usage and other figures: Not disclosed) |
| Source | Japan Institute of Invention and Innovation (National Commendation for Invention) |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The invention was highly evaluated for the technological advancement and implementation results of its drug delivery technology, which delivers biopharmaceuticals to the brain by enabling them to cross the blood-brain barrier.